Bifogade filer
BICO completes the divestment of Nanoscribe
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
As announced on November 21, 2024, BICO Group AB (publ) entered into an agreement to divest Nanoscribe. BICO has as of today completed the divestment.
The transaction was completed at an equity value of EUR 26m (SEK 294m), following net debt and working capital adjustments.
The rationale behind the divestment is in line with the updated strategy, BICO 2.0, where Nanoscribe has been concluded non-core due to its significant footprint outside life science. Net proceeds, following transaction expenses, will be used to reduce long term debt.
The divestment is estimated to generate a capital gain of approximately 10 percent based on book value per Q3 2024.
Final financial impact will be reported in the interim report for Q4 2024. In BICO’s financial reporting Nanoscribe will be treated as discontinued operations from Q4 2024.
For further information on the divestment, please see the press release which was published on November 21, 2024.